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Abstract
Myelodysplastic syndrome (MDS) patients with a normal karyotype constitute a heterogeneous group from a biological stand-
point and their outcome is often unpredictable. Interphase fluorescence in situ hybridization (I-FISH) studies could increase 
the rate of detection of abnormalities, but previous reports in the literature have been contradictory. We performed I-FISH and 
conventional karyotyping (G-banding) on 50 MDS patients at diagnosis, after 6 and 12 months or at any time if a transforma-
tion to acute myeloid leukemia (AML) was detected. Applying a probe-panel targeting the centromere of chromosomes 7 and 
8, 5q31, 5p15.2 and 7q31, we observed one case with 5q deletion not identified by G-banding. I-FISH at 6 and 12 months 
confirmed the karyotype results. Eight cases transformed to AML during follow-up, but no hidden clone was detected by I-FISH 
in any of them. The inclusion of I-FISH during follow-up of MDS resulted in a small improvement in abnormality detection when 
compared with conventional G-banding.
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Myelodysplastic syndrome (MDS) is a clonal hematopoi-
etic stem cell disorder characterized by peripheral cytope-
nias due to ineffective hematopoiesis. Up to 30% of MDS 
patients are at risk to transform to acute leukemia (1). The 
identification of chromosomal abnormalities is crucial to 
determine survival and predict the risk of a transformation 
to acute leukemia (2). Nevertheless, a large proportion of 
MDS patients (40 to 65%) (3) present normal karyotypes at 
diagnosis. In this group, which is highly heterogeneous from 
a biological standpoint, outcome is often unpredictable. 
MDS is usually diagnosed with cytogenetic techniques 
such as G-banding. Some investigators have stated that the 
frequency of chromosomal abnormalities is underestimated 
with conventional techniques such as G-banding because 
the aberrant clone does not proliferate well in cell cultures, 
reducing the possibility of detection (3-5). It has also been 
proposed that hidden clones not detected by conventional 
cytogenetics might be involved in the progression to acute 
leukemia of MDS cases with a normal karyotype (6,7), and 
that other, more sensitive approaches such as interphase 
fluorescent in situ hybridization (I-FISH) would be required 
for detection of occult lesions. 
The purpose of the present study was to determine 
whether I-FISH would be able to detect hidden clones 
associated with the progression of MDS to acute myeloid 
leukemia (AML) that are undetected by conventional G-
banding methods over a 12-month period.
The present study was carried out within the context of 
a wide prospective study evaluating karyotype, FMS-like 
tyrosine kinase 3 (FLT3) internal tandem duplications, the 
French-American-British (FAB) Cooperative Group classifi-
cation, the World Health Organization (WHO) classification 
of neoplastic diseases of the hematopoietic and lymphoid 
tissue, and the International Prognostic Scoring System 
(IPSS). I-FISH and G-banding were performed in 50 MDS 
patients at diagnosis and after 6 and 12 months, or when-
ever AML transformation was detected (8-13). 
Patients and Methods
The group included 48 patients with primary MDS and 2 
with secondary MDS diagnosed from March 2003 to March 
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2006. Patients with de novo and secondary MDS were diag-
nosed according to WHO/FAB criteria (14,15) and classified 
according to the IPSS (2). There were 27 (54%) male and 23 
(46%) female patients. Treatment was based on red blood 
cell and platelet transfusions or bone marrow transplantation 
whenever appropriate. Median follow-up was 19 months 
(range: 2 to 36 months). Information concerning 8 of these 
50 patients has been previously published (8-13). The study 
was approved by the Institution’s Ethics Committee and all 
patients signed an informed consent form.
G-banding analysis was performed at the time of col-
lection following standard protocols (16) and ISCN 2005 
(17). Whenever possible, at least 20 metaphases were 
analyzed. I-FISH was performed on fixed bone marrow cell 
suspensions (5) that had been used for karyotyping and 
stored in Carnoy’s fixative at -20°C. Since the most common 
chromosomal abnormalities in MDS involve chromosomes 
5, 7 and 8, we used probes to detect deletions in these 
chromosomes. The following panel of probes was used: 
CEP 8 (Vysis, Zeis, USA), targeting the centromeric region of 
chromosome 8; LSI EGR1 Spectrum orange/:D5S721, LSI 
D5S23 Spectrum Green (Vysis), targeting 5q31 and 5p15.2, 
respectively, and Spectrum red D7S486, Spectrum green 
D7Z1, targeting 7q31 and 7 centromere (Vysis). The slides 
were prepared and incubated in 70% formamide/2X SSC 
at 73°C for 5 min, dehydrated in ethanol (70, 85 and 100%) 
and air-dried. I-FISH assays were performed following probe 
manufacturer instructions. The slides were analyzed using 
an epifluorescence microscope (Zeiss, Switzerland) with a 
triple band pass filter and single filters for FITC, Texas red 
and DAPI (Power Gene - Image Analysis Software, Applied 
Imaging Corporation, USA). 
A minimum of 200 cells per specimen/probe were 
scored by two independent investigators. In the absence 
of discrepancy the results were reviewed, combined and 
averaged (5). FISH and G-banding were analyzed blindly 
regarding each other. Samples from 9 bone marrow donors 
(without MDS) were used as controls. Based on the rate of 
abnormalities observed in controls plus two standard devia-
tions, the cut-off level for normal values was established 
for each target region (5) as follows: -5 = 3%, del (5q31) = 
3%, -7 = 1.5%, del (7q31) = 0.6%, +8 = 2.7%.
Results
In terms of IPSS, 13 patients were classified as low-risk, 
27 as intermediate 1, 3 as intermediate 2, and 2 as high-
risk for progression to AML. Evaluation was not possible 
in 4 patients. 
G-banding revealed chromosomal abnormalities in 9 of 
44 patients (20.4%) at diagnosis, 9 of 36 patients (25%) at 6 
months and 9 of 29 patients (31%) at 12 months. Sufficient 
metaphases for analysis were not obtained in 6 cases at 
diagnosis, 5 cases at 6 months and 3 cases at 12 months. 
I-FISH revealed abnormalities in 6 of 50 patients (12%) at 
diagnosis, confirming G-banding findings in 5 cases. In one 
case with insufficient metaphases on G-banding, I-FISH 
revealed deletion of 5q. I-FISH results at 6 and 12 months 
confirmed the karyotyping.
During follow-up, the diagnosis of 8 patients became 
AML. Five patients presented chromosomal abnormalities 
at the time of transformation. The FISH panel did not detect 
hidden clones related to AML transformation. Ten patients 
died during the 12-month follow-up period due to severe 
cytopenia or to no response to chemotherapy (after AML 
transformation). 
Discussion
To the best of our knowledge, this is the first study 
to compare the detection of chromosomal abnormalities 
with the I-FISH and G-banding methods over a 12-month 
follow-up period in patients with MDS. I-FISH revealed an 
additional abnormality at diagnosis in only 1 patient (2%), 
i.e., deletion 5q in 1 patient who presented no metaphases 
in karyotype analysis. Notwithstanding its low additional 
benefit, FISH was important to define the best treatment 
for this specific patient, since lenalidomide (Revlimid®, 
Cellgene, USA) induces a complete hematological and 
cytogenetic response in more than 80% of MDS patients 
with 5q deletion (18). 
Several studies have compared FISH and conventional 
cytogenetic analysis at specific times during the develop-
ment of the diseases, most of them showing only a small 
advantage of FISH for detecting chromosomal anomalies. 
Romeo et al. (5) evaluated 40 MDS patients at diagnosis by 
G-banding karyotype and dual-color FISH and reported that 
FISH was able to detect an abnormal clone in 3 of 22 patients 
with a normal karyotype and in 1 of 6 patients with insuf-
ficient metaphases. In a study by the Eastern Cooperative 
Oncology Group (ECOG), only 1 of 48 patients presented 
an occult deletion of chromosome 11 detected by FISH (6). 
Panani and Pappa (19) studied the incidence of trisomy 8 
in 30 primary MDS patients using FISH and G-banding. 
Superiority of FISH over karyotyping was detected in only 
3 (10%) cases. Recently, Chen et al. (20) observed that 
I-FISH, but not G-banding, was able to detect -5/5q- in 5 of 
30 cases, -7/7q- in 3 cases, and trisomy 8 in 5 cases.
Rigolin et al. (3) analyzed 101 patients with primary 
MDS and a normal karyotype and observed 15-32% of 
interphase cells with at least one FISH abnormality. In that 
study, FISH abnormalities were associated with a higher rate 
of progression to AML (13/18 vs 12/83) and were predictive 
of a worse prognosis. It should be noted that the patients in 
the study by Rigolin et al. (3) were mostly in the intermediate 
2 or high-risk IPSS categories. This might explain why an 
increased number of FISH abnormalities or AML evolution 
was detected in relation to the present study, which included 
mostly low-risk and intermediate 1 patients. 
The use of I-FISH during follow-up of MDS did not im-
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prove the detection of abnormalities when compared with 
conventional G-banding. I-FISH should probably be used 
in selected cases for which specific therapeutic options 
must be considered.
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